6.
Chaudhary M, Edmondson-Jones M, Baio G, Mackay E, Penrod J, Sharpe D
. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. Med Decis Making. 2022; 43(1):91-109.
DOI: 10.1177/0272989X221132257.
View
7.
Ades A, Welton N, Caldwell D, Price M, Goubar A, Lu G
. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy. 2008; 13 Suppl 3:12-22.
DOI: 10.1258/jhsrp.2008.008020.
View
8.
Robert C, Thomas L, Bondarenko I, ODay S, Weber J, Garbe C
. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517-26.
DOI: 10.1056/NEJMoa1104621.
View
9.
Balch C, Buzaid A, Soong S, Atkins M, Cascinelli N, Coit D
. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19(16):3635-48.
DOI: 10.1200/JCO.2001.19.16.3635.
View
10.
Maio M, Grob J, Aamdal S, Bondarenko I, Robert C, Thomas L
. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015; 33(10):1191-6.
PMC: 5795709.
DOI: 10.1200/JCO.2014.56.6018.
View
11.
Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A
. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833.
DOI: 10.1056/NEJMoa1606774.
View
12.
Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J
. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550.
DOI: 10.1016/S0140-6736(15)01281-7.
View
13.
Herbst R, Garon E, Kim D, Cho B, Gervais R, Perez-Gracia J
. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. J Thorac Oncol. 2021; 16(10):1718-1732.
DOI: 10.1016/j.jtho.2021.05.001.
View
14.
Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A
. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021; 39(21):2339-2349.
PMC: 8280089.
DOI: 10.1200/JCO.21.00174.
View
15.
Armoiry X, Wang-Steverding X, Connock M, Grove A, Clarke A, Arun T
. Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis. Int J Technol Assess Health Care. 2022; 38(1):e83.
DOI: 10.1017/S0266462322003269.
View
16.
Ayers D, Cope S, Towle K, Mojebi A, Marshall T, Dhanda D
. Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma. BMC Med Res Methodol. 2022; 22(1):272.
PMC: 9569052.
DOI: 10.1186/s12874-022-01745-z.
View
17.
Cope S, Ayers D, Zhang J, Batt K, Jansen J
. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019; 19(1):182.
PMC: 6721254.
DOI: 10.1186/s12874-019-0823-8.
View
18.
Cooney P, White A
. Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation. Med Decis Making. 2023; 43(3):325-336.
PMC: 10021125.
DOI: 10.1177/0272989X221150212.
View
19.
Willigers B, Ouwens M, Briggs A, Heerspink H, Pollock C, Pecoits-Filho R
. The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial. Adv Ther. 2023; 40(6):2741-2751.
PMC: 10220142.
DOI: 10.1007/s12325-023-02503-3.
View
20.
Tan Y, Papez V, Chang W, Mueller S, Denaxas S, Lai A
. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022; 3(10):e674-e689.
DOI: 10.1016/S2666-7568(22)00186-6.
View